China Liver Cancer Clinical Registry Cohort Database (HEAL)
1 other identifier
observational
10,000
1 country
38
Brief Summary
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2025
Longer than P75 for all trials
38 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2025
CompletedFirst Submitted
Initial submission to the registry
January 14, 2025
CompletedFirst Posted
Study publicly available on registry
January 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2035
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2035
August 20, 2025
August 1, 2025
10 years
January 14, 2025
August 15, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
OS
Time from enrollment to first recorded occurrence of death from any cause
10 years
Secondary Outcomes (2)
RFS
10 years
Survival time after recurrence
10 years
Study Arms (1)
Liver Cancer
Observation of clinical routine treatment in patients with Liver cancer
Interventions
Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC
Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
Eligibility Criteria
Patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined hepatocellular carcinoma-cholangiocarcinoma, or metastatic liver cancer.
You may qualify if:
- Age ≥ 18 years, no gender limit
- Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
- Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples
You may not qualify if:
- Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
- Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
- Pregnant or breastfeeding women
- Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (38)
Anqing First People's Hospital
Anqing, Anhui, 246000, China
Anqing Municipal Hospital
Anqing, Anhui, 246003, China
Bengbu First People's Hospital
Bengbu, Anhui, 233000, China
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, 233000, China
The Second Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233000, China
The People's Hospital of Bozhou
Bozhou, Anhui, 236000, China
The People's Hospital of Chizhou
Chizhou, Anhui, 247000, China
The First People's Hospital of Chuzhou
Chuzhou, Anhui, 239001, China
No.2 People's Hospital of Fuyang City
Fuyang, Anhui, 236015, China
Fuyang Cancer Hospital
Fuyang, Anhui, 236100, China
Fuyang Fifth People's Hospital
Fuyang, Anhui, 236100, China
Fuyang People's Hospital
Fuyang, Anhui, 236100, China
Fuyang Sixth People's Hospital
Fuyang, Anhui, 236100, China
Funan County People's Hospital
Fuyang, Anhui, 236300, China
Taihe County People's Hospital
Fuyang, Anhui, 236600, China
Anhui province hospital
Hefei, Anhui, 230000, China
Anhui Provincial Cancer Hospital
Hefei, Anhui, 230000, China
Hefei Binhu Hospital
Hefei, Anhui, 230000, China
Hefei First People's Hospital
Hefei, Anhui, 230000, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
The Second Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
The Second People's Hospital of Hefei
Hefei, Anhui, 230000, China
Anhui Second People's Hospital
Hefei, Anhui, 230041, China
Huaibei Mining General Hospital
Huaibei, Anhui, 235000, China
Huaibei People's Hospital
Huaibei, Anhui, 235000, China
Huainan First People's Hospital
Huainan, Anhui, 232000, China
Huainan Oriental Hospital
Huainan, Anhui, 232000, China
Huainan Sunshine Xinkang Hospital
Huainan, Anhui, 232000, China
Huainan Xinhua Hospital
Huainan, Anhui, 232000, China
Huangshan City People's Hospital
Huangshan City, Anhui, 242700, China
Huangshan Shoukang Hospital
Huangshan City, Anhui, 242700, China
Lu'an People's Hospital
Lu'an, Anhui, 237000, China
Suzhou Hospital of Anhui Medical University
Suzhou, Anhui, 234000, China
Tongling People's Hospital
Tongling, Anhui, 244000, China
The Second People's Hospital of Wuhu
Wuhu, Anhui, 241000, China
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, 241001, China
Xuancheng People's Hospital
Xuancheng, Anhui, 242000, China
Henan Provincial People's Hospital
Zhengzhou, Henan, 450000, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 14, 2025
First Posted
January 15, 2025
Study Start
January 1, 2025
Primary Completion (Estimated)
January 1, 2035
Study Completion (Estimated)
January 1, 2035
Last Updated
August 20, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share